Antios Therapeutics to present at HEP DART 2019 Meeting

ATLANTA, Ga., Dec. 9, 2019 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced the acceptance of an oral presentation at the 23^rd biennial HEP DART meeting being held December 8-12, 2019 in Kauai, Hawaii.

Douglas Mayers, M.D., Chief Medical Officer of Antios, will present: "ATI-2173, A Novel HBV Nucleoside Phosphoramidate for HBV Cure Regimens."

The oral presentation will take place on December 9, 2019 during Oral Abstract Session I, and will include data demonstrating potent in-vitro anti-HBV activity and significant liver-targeting of ATI-2173 in rat and monkey studies.

About ATI-2173

ATI-2173 is novel liver-targeted molecule designed to deliver the 5'-monophosphate of clevudine. This L-nucleoside's active 5'-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor. By selectively delivering the 5'-monophosphate to the liver, while retaining the unique anti-HBV activity of the active 5'- triphosphate, ATI-2173 could become an integral part of a curative combination regimen for chronic hepatitis B.

About Antios Therapeutics Inc.

Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.

CONTACT: pr@antiostherapeutics.com

View original content:http://www.prnewswire.com/news-releases/antios-therapeutics-to-present-at-hep-dart-2019-meeting-300970898.html

SOURCE Antios Therapeutics, Inc.